blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP4039818

EP4039818 - METHOD FOR PROGNOSING THE COURSE OF A SARS-COV-2 INFECTION AND THE RESPONSE TO A SARS-COV-2 IMMUNIZATION AND/OR NATURAL INFECTION BY MEASURING SOLUBLE ACE2 [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  16.06.2023
Database last updated on 03.10.2024
FormerThe application has been published
Status updated on  08.07.2022
Most recent event   Tooltip16.06.2023Application deemed to be withdrawnpublished on 19.07.2023  [2023/29]
Applicant(s)For all designated states
Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft
Robert-Rössle-Straße 10
13125 Berlin / DE
For all designated states
Charité - Universitätsmedizin Berlin
Charitéplatz 1
10117 Berlin / DE
[N/P]
Former [2022/32]For all designated states
Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft
Robert-Rössle-Strasse 10
13125 Berlin / DE
For all designated states
Charité - Universitätsmedizin Berlin
Charitéplatz 1
10117 Berlin / DE
Inventor(s)01 / De la Rosa, Kathrin
10437 Berlin / DE
02 / Lebedin, Mikhail
16321 Bernau / DE
03 / Sander, Leif
14169 Berlin / DE
04 / Kurth, Florian
10555 Berlin / DE
 [2022/32]
Representative(s)Kador & Partner Part mbB
Corneliusstraße 15
80469 München / DE
[N/P]
Former [2022/32]Kador & Partner PartG mbB
Corneliusstraße 15
80469 München / DE
Application number, filing date21155584.205.02.2021
[2022/32]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP4039818
Date:10.08.2022
Language:EN
[2022/32]
Search report(s)(Supplementary) European search report - dispatched on:EP30.09.2021
ClassificationIPC:C12Q1/37, G01N33/566, G01N33/68
[2022/32]
CPC:
C12Q1/37 (EP); G01N33/566 (EP); G01N33/6893 (EP);
G01N2800/26 (EP); G01N2800/52 (EP)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2022/32]
Extension statesBANot yet paid
MENot yet paid
Validation statesKHNot yet paid
MANot yet paid
MDNot yet paid
TNNot yet paid
TitleGerman:VERFAHREN ZUR PROGNOSE DES VERLAUFS EINER SARS-COV-2-INFEKTION UND DER REAKTION AUF EINE SARS-COV-2-IMMUNISIERUNG UND/ODER AUF EINE NATÜRLICHE INFEKTION DURCH MESSUNG VON LÖSLICHEM ACE2[2022/32]
English:METHOD FOR PROGNOSING THE COURSE OF A SARS-COV-2 INFECTION AND THE RESPONSE TO A SARS-COV-2 IMMUNIZATION AND/OR NATURAL INFECTION BY MEASURING SOLUBLE ACE2[2022/32]
French:PROCÉDÉ DE PRONOSTIC DE L'ÉVOLUTION D'UNE INFECTION AU SARS-COV-2 ET DE LA RÉPONSE À UNE IMMUNISATION CONTRE LE SARS-COV-2 OU À UNE INFECTION NATURELLE EN MESURANT LA QUANTITÉ D`ACE2 SOLUBLE[2022/32]
Examination procedure11.02.2023Application deemed to be withdrawn, date of legal effect  [2023/29]
03.03.2023Despatch of communication that the application is deemed to be withdrawn, reason: examination fee not paid in time  [2023/29]
Fees paidPenalty fee
Additional fee for renewal fee
28.02.202303   M06   Not yet paid
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[X]CN112017782  (BEIJING SONGGUOTIANMU HEALTH MAN CO LTD) [X] 8 * abstract; Fig. 1; Description *;
 [X]  - RICE GILLIAN I. ET AL, "Circulating Activities of Angiotensin-Converting Enzyme, Its Homolog, Angiotensin-Converting Enzyme 2, and Neprilysin in a Family Study", HYPERTENSION, US, (20061101), vol. 48, no. 5, doi:10.1161/01.HYP.0000244543.91937.79, ISSN 0194-911X, pages 914 - 920, XP055820382 [X] 1-4,13,15 * p. 915, par.: "Assays" *

DOI:   http://dx.doi.org/10.1161/01.HYP.0000244543.91937.79
    [ ] - Rice Gillian I ET AL, "Supplementary Information_Circulating Activities of Angiotensin Converting Enzyme (ACE), its Homolog ACE2 and Neprilysin in a Family Study", (20061101), URL: https://www.ahajournals.org/doi/suppl/10.1161/01.HYP.0000244543.91937.79, (20210701), XP055820424 [ ] * par.: "Assays" *
 [X]  - Xiao Fengxia ET AL, "Measurement of Angiotensin Converting Enzyme 2 Activity in Biological Fluid (ACE2) : Methods and Protocols", Hypertension : Methods and Protocols, Humana Press, (20170101), vol. 1527, pages 101 - 115, doi:10.1007/978-1-4939-6625-7_8, ISSN 1064-3745, XP055820414 [X] 1-4,13,15 * p. 102-103, par.: 2 Materials; p. 102-107, par. 3 Methods; p. 110-111 *

DOI:   http://dx.doi.org/10.1007/978-1-4939-6625-7_8
 [X]  - ÚRI KATALIN ET AL, "New Perspectives in the Renin-Angiotensin-Aldosterone System (RAAS) IV: Circulating ACE2 as a Biomarker of Systolic Dysfunction in Human Hypertension and Heart Failure", PLOS ONE, vol. 9, no. 4, doi:10.1371/journal.pone.0087845, (20140401), pages e87845 - ] e87845, URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3972189/pdf/pone.0087845.pdf, XP055820690 [X] 1-4,13,15 * p. 3, par.: "Measurement of serum ACE2 activity" *

DOI:   http://dx.doi.org/10.1371/journal.pone.0087845
 [X]  - KATALIN URI ET AL, "Circulating ACE2 activity correlates with cardiovascular disease development", JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM., (20161212), pages 1 - 11, URL: https://journals.sagepub.com/doi/pdf/10.1177/1470320316668435, XP055820680 [X] 1-4,13,15 * p. 3, par.: Measurement of serum ACE2 activity *
 [X]  - NAGY BÉLA ET AL, "A dramatic rise in serum ACE2 activity in a critically ill COVID-19 patient", INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, INTERNATIONAL SOCIETY FOR INFECTIOUS DISEASES, HAMILTON, CA, vol. 103, doi:10.1016/J.IJID.2020.11.184, ISSN 1201-9712, (20201126), pages 412 - 414, (20201126), XP086488977 [X] 1-4,8,13,15,16 * p. 413, co. 2; abstract; p. 414 *

DOI:   http://dx.doi.org/10.1016/j.ijid.2020.11.184
 [X]  - Anonymous, "Mca-APK(Dnp) - BML-P163 - Enzo Life Sciences", (20170125), pages 1 - 2, URL: https://www.enzolifesciences.com/BML-P163/mca-apk-dnp/, (20210702), XP055820671 [X] 13,15 * the whole document *
 [X]  - LI WENHUI ET AL, "Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus", NATURE, MACMILLAN JOURNALS LTD., ETC, LONDON, (20031101), vol. 426, no. 6965, doi:10.1038/NATURE02145, ISSN 0028-0836, pages 450 - 454, XP037065772 [X] 5-7,14,15 * p. 453, co. 2, par.: Immunoprecipitation and identification of ACE2 *

DOI:   http://dx.doi.org/10.1038/nature02145
 [X]  - Lier D.P.T. Van ET AL, "Increased blood angiotensin converting enzyme 2 activity in critically ill COVID-19 patients", ERJ open research, England, doi:10.1183/23120541.00848-2020, (20210128), page 848, URL: https://openres.ersjournals.com/content/erjor/early/2021/01/21/23120541.00848-2020.full.pdf, (20210921), XP055842962 [X] 8-12,16 * par.: "Methods"; fig. 1; par.: "Discussion" *

DOI:   http://dx.doi.org/10.1183/23120541.00848-2020
 [A]  - BENTON DONALD J ET AL, "Receptor binding and priming of the spike protein of SARS-CoV-2 for membrane fusion", NATURE, (20201220), vol. 588, no. 7837, doi:10.1038/S41586-020-2772-0, ISSN 0028-0836, pages 327 - 330, XP037313512 [A] 1-16 * the whole document *

DOI:   http://dx.doi.org/10.1038/s41586-020-2772-0
by applicant   - ELASED, K.M.CUNHA, T.S.GURLEY, S.B.COFFMAN, T.M.MORRIS, M., "New mass spectrometric assay for angiotensin-converting enzyme 2 activity", Hypertension, (20060000), vol. 47, pages 1010 - 1017
    - PICCOLI, L.PARK, Y.-J.TORTORICI, M.A.CZUDNOCHOWSKI, N.WALLS, A.C.BELTRAMELLO, M.SILACCI-FREGNI, C.PINTO, D.ROSEN, L.E.BOWEN, J.E., "Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology", Cell, (20200000), vol. 183, pages 1024 - 1042
    - PINTO, D.PARK, Y.-J.BELTRAMELLO, M.WALLS, A.C.TORTORICI, M.A.BIANCHI, S.JACONI, S.CULAP, K.ZATTA, F.DE MARCO, A., "Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody", Nature, (20200000), vol. 583, doi:10.1038/s41586-020-2349-y, pages 290 - 295, XP037289888

DOI:   http://dx.doi.org/10.1038/s41586-020-2349-y
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.